ABILIFY®

Drug Information Related Patent
Hold Company
OTSUKA
Learn More
Dosage and Administration
TABLET;ORAL
Specification
10MG; 15MG; 20MG; 30MG; 5MG; 2MG
Indication
ABILIFY® is indicated for the treatment of schizophrenia, bipolar I mania and mixed episodes, major depression, irritability associated with autism, and Tourette's disease.
Use
Instructions for Use
API
ARIPIPRAZOLE
API Structure
We Supply
ARIPIPRAZOLE
Note:

In-house Standard/EP/USP
Facility GMP
USMF/CDE/CEP

null
Note:

null

null
Note:

null

Drug Patent
Patent NoExpiration Date
80176152024/6/16
8017615*PED2024/12/16
87593502027/3/2
91259392026/7/28
93871822023/12/25
API Patent
Patent NoExpiration Date
80176152024/6/16
8017615*PED2024/12/16
HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen-ING. All Rights Reserved.
dcat
Member of
dcat
Top